1. Home
  2. FNCH

FNCH

Finch Therapeutics Group Inc.

Logo Finch Therapeutics Group Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Founded: 2017 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 3.6M IPO Year: 2021
Target Price: $210.00 AVG Volume (30 days): 31.4K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -46.59 EPS Growth: N/A
52 Week Low/High: $1.87 - $16.74 Next Earning Date: 05-08-2024
Revenue: $107,000 Revenue Growth: -87.57%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: